Science

Yuji Uehara: Resistance to osimertinib in EGFR-mutated LUAD

Yuji Uehara/X

Dec 20, 2024, 14:12

Yuji Uehara: Resistance to osimertinib in EGFR-mutated LUAD

Yuji Uehara, Medical Oncologist, National Cancer Center, Japan, shared a post on X about a recent study by him and colleagues published in Journal of Thoracic Oncology:

“Hot Off the Press from our study: Solid histology and high podoplanin CAFs predict resistance to osimertinib in EGFR-mutated LUAD.

Key Findings:

Solid histology/High podoplanin CAFs: Worse PFS and OS for Osimertinib – HGF Expression is higher in these tumors.
Could identify patients for intensive therapy targeting MET + EGFR (e.g., Ami + Lazer).”

Solid predominant histology and high podoplanin expression in cancer-associated fibroblast predict primary resistance to osimertinib in EGFR-mutated lung adenocarcinoma

Authors: Yuji Uehara et al.

Yuji Uehara: Resistance to osimertinib in EGFR-mutated LUAD

More posts featuring Yuji Uehara.

cancer EGFR-mutated LUAD Eri Sugiyama Genichiro Ishi Hibiki Udagawa Hiroki Izumi Keiju Aokage Kiyotaka Yoh Koichi Goto lung adenocarcinoma Masahiro Tsuboi Michiko Nagamine Motohiro Kojima Naoya Sakamoto OncoDaily Oncology osimertinib Shigeki Umemura Shingo Matsumoto Shingo Sakashita Shoko Kubota Tetsuro Taki Tetsuya Sakai Yoshitaka Zenke Yuji Uehara Yukio Hosomi

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

Special Coverage